<DOC>
	<DOCNO>NCT00873002</DOCNO>
	<brief_summary>RATIONALE : Panobinostat sorafenib may stop growth tumor cell block enzymes need cell growth . Sorafenib may also stop growth liver cancer block blood flow tumor . PURPOSE : This phase I trial study side effect best dose panobinostat give together sorafenib treat patient liver cancer metastatic and/or remove surgery .</brief_summary>
	<brief_title>Panobinostat Sorafenib Treating Patients With Liver Cancer That Metastatic and/or Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess safety tolerability panobinostat combine standard dos sorafenib tosylate patient metastatic and/or unresectable hepatocellular carcinoma . - Determine maximum tolerate dose panobinostat combine standard dos sorafenib tosylate patient . Secondary - Determine response rate . - Determine progression-free survival . - Determine overall survival rate . OUTLINE : This dose escalation study panobinostat . Patients receive panobinostat IV day 1 8 oral sorafenib tosylate twice daily day 1-21 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study therapy , patient follow 30 day .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm hepatocellular carcinoma Metastatic and/or unresectable disease ChildPugh score A B PATIENT CHARACTERISTICS : ECOG performance status 02 Neutrophil count &gt; 1500/mm³ Platelet count &gt; 100,000/mm³ Hemoglobin ≥ 9 g/dL AST ALT ≤ 2.5 time upper limit normal ( ULN ) ( ≤ 5.0 time ULN elevation due disease involvement ) Serum bilirubin ≤ 1.5 time ULN Serum creatinine ≤ 1.5 time ULN creatinine clearance ≥ 50 mL/min Total serum calcium ( correct serum albumin ) ionize calcium ≥ low limit normal ( LLN ) Serum potassium ≥ LLN Serum sodium ≥ LLN Serum albumin ≥ LLN 3 g/dL LVEF ≥ LLN demonstrate baseline MUGA ECHO TSH free T4 within normal limit ( thyroid hormone replacement therapy allow ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublemethod contraception ( one barrier method ) 3 month completion study treatment INR &lt; 1.5 PT/PTT within normal limit No impaired cardiac function include 1 following : QTc &gt; 450 msec screen ECG Congenital long QT syndrome History sustain ventricular tachycardia History ventricular fibrillation torsades de pointes Bradycardia , define heart rate &lt; 50 beat per minute Patients pacemaker heart rate ≥ 50 beat per minute eligible Myocardial infarction unstable angina within past 6 month Congestive heart failure ( NYHA class IIIIV ) Right bundle branch block leave anterior hemiblock ( bifascicular block ) No uncontrolled hypertension No thrombolic embolic event ( e.g. , cerebrovascular accident transient ischemic attack ) within past 6 month No pulmonary hemorrhage/bleeding event &gt; CTCAE Grade 2 within past 4 week No hemorrhage/bleeding event &gt; CTCAE Grade 3 within past 4 week No unresolved diarrhea &gt; CTCAE grade 1 No concurrent severe and/or uncontrolled medical condition No primary malignancy within past 5 year except curatively treat carcinoma situ cervix basal cell squamous cell carcinoma skin No serious nonhealing wound , ulcer , bone fracture No evidence history bleed diathesis coagulopathy No significant traumatic injury within past 4 week No know suspect allergy sorafenib tosylate study drug No condition would impair patient 's ability swallow whole pill No malabsorption problem No known human immunodeficiency virus ( HIV ) hepatitis C positivity ( baseline test HIV hepatitis C require ) No significant history noncompliance medical regimen PRIOR CONCURRENT THERAPY : No prior HDAC inhibitor , DAC inhibitor , HSP90 inhibitor , sorafenib tosylate , valproic acid treatment cancer More 4 week since prior chemotherapy , investigational drug , major surgery recover More 4 week since open biopsy More 5 day since prior concurrent valproic acid medical condition No concurrent St. John 's wort rifampin No concurrent drug risk cause torsades de point No concurrent CYP3A4 inhibitors No concurrent radiotherapy No concurrent grapefruit , grapefruit juice , Seville ( sour ) oranges No concurrent investigational therapy No concurrent anticancer agent Concurrent anticoagulation treatment warfarin heparin allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
</DOC>